How do Bimzelx and Taltz work?
Bimzelx (bimekizumab) blocks both IL-17A and IL-17F cytokines, targeting inflammation in conditions like psoriasis and psoriatic arthritis. Taltz (ixekizumab) selectively blocks only IL-17A.[1][2]
What conditions do they treat?
Both FDA-approved for moderate-to-severe plaque psoriasis in adults and kids 6+ years, as well as psoriatic arthritis and axial spondyloarthritis. Bimzelx also covers non-radiographic axial spondyloarthritis; Taltz adds ankylosing spondylitis and hidradenitis suppurativa.[1][2]
How are they dosed and administered?
Both are subcutaneous injections. Bimzelx starts with 320 mg (two 160 mg doses) at weeks 0, 4, 8, 12, then every 8 weeks. Taltz starts at 160 mg week 0, 80 mg every 2 weeks through week 12, then every 4 weeks.[1][2]
| Feature | Bimzelx | Taltz |
|---------|---------|-------|
| Initial dose | 320 mg (2 injections) | 160 mg (1 injection) |
| Maintenance interval | Every 8 weeks | Every 4 weeks |
| Auto-injector | Prefilled syringe or pen | Prefilled auto-injector |
How do their efficacy and safety profiles compare?
Clinical trials show both clear skin in 80-90% of psoriasis patients at week 16, but Bimzelx achieves full clearance (PASI 100) faster and more often due to dual IL-17 blockade. Taltz has longer real-world data. Common side effects overlap: upper respiratory infections, injection site reactions, fungal infections. Bimzelx reports slightly higher oral candidiasis risk; Taltz links to rare inflammatory bowel disease flares.[1][2][3]
Who makes them and what's the pricing like?
Bimzelx is from UCB; Taltz from Eli Lilly. List prices are similar at ~$6,000-7,000 per month before discounts or insurance. Patient assistance programs vary by manufacturer.[1][2]
When do patents expire?
Taltz's key composition patent expires in 2033-2034 in the US, with extensions possible. Bimzelx's main patents run to 2036-2039, delaying biosimilars longer.4
[1]: Bimzelx prescribing information, FDA.gov
[2]: Taltz prescribing information, FDA.gov
[3]: Head-to-head trials in NEJM (2021) and Lancet (2023)